Search results for Ocrelizumab

Ocrelizumab Biosimilar – Anti-MS4A1, CD20 mAb – Research Grade, ProteoGenix, PX-TA1162

Description of Ocrelizumab Biosimilar - Anti-MS4A1, CD20 mAb - Research Grade General information on Anti-MS4A1/CD20(Homo sapiens) (Ocrelizumab) Monoclonal Antibody Ocrelizumab is a CD20-directed cytolytic antibody, which is suitable for the treatment of patients with relapsed or primary progressive multiple sclerosis. It is a second-generation recombinant humanized monoclonal antibody of isotype IgG1 that can selectively target B lymphocytes expressing CD20 antigen. Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system, which can cause neurological dysfunction. Most patients with MS experience recurrent episodes with functional deterioration, followed by recovery or remission.

Ocrelizumab, Abbexa, abx831117

Ocrelizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting MS4A1/CD20, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis. It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets the B lymphocytes that express the CD20 antigen. As a humanized molecule, ocrelizumab is expected to be less immunogenic with repeated infusions which improves the benefit-to-risk profile for patients with relapsing or progressive forms of MS.

Ocrelizumab Antibody, Abbexa, abx376609

Ocrelizumab Antibody is a rabbit polyclonal antibody for the detection of Ocrelizumab.

Anti-Ocrelizumab Polyclonal Antibody, AntibodySystem, PAC90703

Ocrelizumab Biosimilar - Research Grade, ichor.bio, ICH5314

Detects human CD20

Research Grade Ocrelizumab (HY257026), abinScience, HY257026

Anti-Ocrelizumab Non-Neutralizing Antibody (SAA2631), ProteoGenix, PTX27135